Miljana Dzunic

Dr. Miljana Dzunic


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019
Verified
Journal Article
Closed access
MDMiljana Dzunic
Miljana Dzunic
Ivan Z PetkovićIvan Z Petković
Ivan Z Petković
ACAna Cvetanovic
Ana Cvetanovic
SVSvetislav Vrbic
Svetislav Vrbic
IPIvica Pejcic
Ivica Pejcic

1 January 2020
Verified
Journal Article
Closed access
MDMiljana Dzunic
Miljana Dzunic
MAMarija Andjelkovic-Apostolovic
Marija Andjelkovic-Apostolovic
SVSvetislav Vrbic
Svetislav Vrbic
IPIvica Pejcic
Ivica Pejcic
Ivan Z PetkovićIvan Z Petković
Ivan Z Petković
SDSasa Dinic
Sasa Dinic

Verified
Journal Article
Open access
PDF file
Ivan Z PetkovićIvan Z Petković
Ivan Z Petković
Michele Pio RitucciMichele Pio Ritucci
Michele Pio Ritucci
ASAna Siniša Stojković
Ana Siniša Stojković
SSSlavica Stojnev
Slavica Stojnev
APAleksandar Popović
Aleksandar Popović
MKMiljan Krstić
Miljan Krstić
T/NK-cell neoplasms represent rare and highly diverse cancers, distinguished by variability in their molecular architecture, local inflammatory milieu, and microenvironmental composition, which collectively underpin the diversity of clinical presentations and outcomes. The neoplastic tissue comprises malignant lymphoma/leukemic cells in concert with a spectrum of stromal elements and the acellular extracellular matrix (ECM), collectively constituting the lymphoma microenvironment (LME). These components engage in dynamic, reciprocal interactions, forming a self-regulating ecosystem capable of responding adaptively to both exogenous and endogenous stimuli. Historically, the LME was largely neglected in considerations of lymphomagenesis; however, emerging evidence highlights its pivotal role in driving core oncogenic processes, including sustained proliferative signaling, angiogenesis, immune evasion, and apoptotic resistance. Deciphering the intricate, multidirectional crosstalk among the cellular and acellular constituents of the T/NK-cell neoplastic microenvironment promises to deepen our understanding of disease biology and may inform the development of novel, mechanism-based therapeutic interventions.

1 December 2019 in AFMN Biomedicine
Verified
Journal Article
Open access
PDF file
MDMiljana Dzunic
Miljana Dzunic
Ivan Z PetkovićIvan Z Petković
Ivan Z Petković
ACAna Cvetanović
Ana Cvetanović
IPIvica Pejčić
Ivica Pejčić
SVSvetislav Vrbić
Svetislav Vrbić
SDSaša Dinić
Saša Dinić
The aim of the research was to investigate prognostic factors in patients with resected colorectal liver metastases (CLMs) after biological and chemotherapy, which made initially unresectable disease suitable for resection. Sixty-six patients with resected CLMs, operated after induction bio-chemotherapy with bevacizumab + FOLFOX4, treated at the Clinic of Oncology, Clinical Center Niš from 2010 - 2017 were included. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test according to demographic characteristics, characteristics of the disease and the treatment. A univariate COX regression analysis was performed. In patients with up to 4 CLMs, DFS was significantly longer than in patients with five or more metastases (18,384 v.s. 6,85 months; p < 0,001). Significantly longer OS was present in patients with up to four CLMs than in those with five or more CLMs (44,687 v.s. 29,723 months; p = 0,006) and in patients without extrahepatic disease (41,71 v.s. 23,283 months; p = 0,012). In the univariate analysis, five or more CLMs were predictors of poorer DFS (HR 3,989; 95% CI 1,055 - 15,087; p = 0,042), whereas the absence of extrahepatic disease was a predictor of better OS (HR 0,122; 95% CI 0,017 - 0,869; p = 0,036). Results of this research are in concordance with previous larger studies in patients with resected CLMs. The number of hepatic and the presence of extrahepatic metastases are prognostic parameters in patients with resected CLM after conversion bio-chemotherapy.

1 December 2022 in AFMN Biomedicine
Verified
Journal Article
Open access
PDF file
MDMiljana Dzunic
Miljana Dzunic
ACAna Cvetanovic
Ana Cvetanovic
Ivan Z PetkovićIvan Z Petković
Ivan Z Petković
Colorectal cancer is the third most common cancer and metastatic disease is an important and frequent clinical problem. Metastases in the oral and maxillofacial region are rare, comprising 1-2% of all malignant lesions, and clinically resemble common benign conditions. A 59-year-old woman diagnosed with rectal cancer developed perimandibular lesion as a first sign of metastatic process. Metastasis manifested clinically during the curative intent treatment of rectal cancer (preoperative chemo-irradiation) as a rapidly growing tumefaction close to the mandible angle. After the biopsy and histopathological examination of the lesion that clinically resembled abscess, metastasis of rectal cancer was diagnosed. Incidentally, a cerebral metastasis was diagnosed as well. Although it was oligometastatic rectal cancer, surgical treatment was not indicated due to extensive infiltrative characteristics of the perimandibular lesion. The patient was treated with chemotherapy, with good clinical response. Biological therapy was not available at that moment. Cerebral metastasis was treated with stereotactic neuroradiosurgery with gamma knife. Unfortunately, the patient died from cerebrovascular insult. Lesions in the oral and maxillofacial region may be the first manifestation of metastatic disease. Since early diagnosis of metastatic process has prognostic implications, any new formation in the oral and maxillofacial region in a patient with colorectal cancer requires cautious observation and histological examination.

31 October 2025 in AFMN Biomedicine
Verified
Journal Article
Open access
PDF file
Ivan Z PetkovićIvan Z Petković
Ivan Z Petković
MEMarija Elez
Marija Elez
APAleksandar Popović
Aleksandar Popović
SSSlavica Stojnev
Slavica Stojnev
ICIrena Conic
Irena Conic
DKDane Krtinic
Dane Krtinic
Although diffuse large B-cell lymphoma (DLBCL) represents a paradigm of highly curative disease with a complete remission (CR) rate of ≈ 60%–70% in an upfront setting, the remaining 30%–40% of patients present a relapse/refractory setting. These population are highly critical and amended for salvage treatment approach. Novel approaches and agents can overcome a problem in 20%–25%. Regarding this problem, polatuzumab vedotine represents one of the options. The use of this agent as bridging to further consolidation has been introduced from the real world experience with encouraging results. We present a 54-year-old male patient diagnosed with primary gastric relapse/refractory (R/R) DLBCL who had been successfully treated by the introduction of antibody-drug conjugate polatuzumab-vedotine. After achieving complete response patient has been further consolidated with a high-dose chemotherapy followed by autologous graft. Given the lack of availability of cellular therapies in developing countries, antibody-drug conjugate may be a plausible approach.